Last updated: January 10, 2024
Sponsor: Møreforsking AS
Overall Status: Active - Recruiting
Phase
N/A
Condition
Atopic Dermatitis
Allergy
Rash
Treatment
LC-MUFA oil
Placebo
Clinical Study ID
NCT06194045
589440
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Women and men 18-80 years of age.
- Diagnosed with active mild to moderate atopic dermatitis with an EASI of 1.1- 21.0.
- Willing to refrain from oil supplements (omega-3, borage, evening primrose, etc.) for 1 month before study begin (washout) and during the study
- Willing to take the study supplement for 6 months
Exclusion
Exclusion Criteria:
- Known allergy to fish products
- Subjects known to be pregnant or breast feeding
- Subjects perceiving systemically administered medication for AD (other than topical)
- Subjects with auto-immune diseases (except asthma and seasonal/perennial rhinitis)
- Subjects with a diagnosis of other skin diseases
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: LC-MUFA oil
Phase:
Study Start date:
December 01, 2023
Estimated Completion Date:
October 10, 2024
Study Description
Connect with a study center
Helse Møre og Romsdal HF
Ålesund, Møre Og Romsdal 6017
NorwayActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.